The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 36 of the 62 sources its claims cite were checked for support.
Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
Open accessAbstract
The purpose of this review is to describe the available data for brexpiprazole in the maintenance treatment of schizophrenia. This objective was completed by searching the databases PubMed, Embase, and ClinicalTrials.gov to identify relevant study results presented as papers or abstracts. In summary, brexpiprazole is a new agent in the D 2 partial agonist class that has a unique receptor-binding profile, based in part on high affinity for serotonin 5HT 1A and 5HT 2A receptors, paired with lower intrinsic activity at dopamine D 2 receptors. The average dose used in efficacy and safety studies for the maintenance treatment of schizophrenia ranged from 3.0 and 3.1 mg in the open-label safety studies to 3.6 mg in the double-blind randomized relapse-prevention study. Highlights from the 52-week double-blind placebo-controlled relapse-prevention trial evidenced rates of relapse in the brexpiprazole group of 13.5% vs 38.5% in the placebo group (number needed to treat 4, 95% CI 3–8; P <0.0001). Safety data indicate that brexpiprazole is tolerated well, with rates of discontinuation due to treatment-emergent adverse events that ranged from 5.2% of those taking brexpiprazole in the double-blind maintenance phase of the relapse-prevention trial to 15.3% in a 52-week open-label safety study. In the available trials, there were relatively low rates of akathisia, and the degree of weight gain was similar to that seen in studies with aripiprazole for the treatment of schizophrenia. Positive and Negative Syndrome Scale scores also remained relatively stable in the open-label safety studies. Available data indicate that brexpiprazole is an effective agent for the maintenance treatment of schizophrenia that is overall well tolerated. Keywords: akathisia, weight gain, second-generation antipsychotics, atypical antipsychotics, relapse prevention
Overview
CoChat Summary
TL;DR
This evidence-based review summarizes brexpiprazole for maintenance treatment of schizophrenia in adults, focusing on three 52-week phase III trials and related analyses. It concludes that brexpiprazole is effective for relapse prevention and generally well tolerated, with low akathisia and weight gain similar to aripiprazole.
Key findings
- In the 52-week randomized, double-blind, placebo-controlled relapse-prevention trial, impending relapse occurred in 13.5% of brexpiprazole-treated patients vs 38.5% with placebo (number needed to treat 4, 95% CI 3–8; P<0.0001); time to impending relapse favored brexpiprazole (HR 0.292, 95% CI 0.156–0.548, P<0.0001).
- Discontinuation due to treatment-emergent adverse events ranged from 5.2% in the double-blind maintenance phase of the relapse-prevention trial to 15.3% in a 52-week open-label safety study.
- Akathisia rates were relatively low, and weight gain appeared similar to aripiprazole; by week 52, average weight gain was 3.2 kg with brexpiprazole vs 4.0 kg with aripiprazole, and weight increase ≥7% was 18.6% vs 25.3%, respectively.
- In open-label safety studies, Positive and Negative Syndrome Scale scores remained relatively stable; average daily doses were 3.0–3.1 mg in open-label studies and 3.6 mg in the double-blind relapse-prevention study.
Methods
- Narrative evidence-based review; PubMed, Embase, and ClinicalTrials.gov were searched for brexpiprazole maintenance-treatment study results, with the first search on September 26, 2018, and additional entries identified through November 4, 2018.
- The search identified 60 PubMed entries, 152 Embase entries, and 35 ClinicalTrials.gov trials, including three 52-week phase III trials: two open-label flexible-dose safety studies and one randomized, double-blind, placebo-controlled relapse-prevention trial.
- The review summarizes pharmacology, pharmacokinetics, long-term efficacy and safety data, and comparative/cost/titration analyses.
Limitations
- The paper states limitations of the long-term investigations: lack of an active comparator, strict inclusion criteria not necessarily reflective of clinical settings, and possible enrichment of the study population by including patients from previous phase III trials who tolerated brexpiprazole.
- The paper notes very few safety data in patients with schizophrenia >65 years old, limited direct comparisons with other antipsychotics or in patients with comorbid psychiatric disease/medication use, and that tablets are the only available dosage form.
- Evident from the text: the relapse-prevention trial was terminated early after the first interim analysis, and only 23 participants received brexpiprazole through week 52 in that trial, limiting long-term exposure data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
34 Valid · 1 Not valid · 22 Not checked · 40 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Higher rates of clinically relevant weight gain, identified as ≥7%, were more likely to occur in the stabilization phase (11.3%) over the maintenance phase (5.2%) for patients taking brexpiprazole.”
§ Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy > Methods > Relapse-prevention trial
What the sources say
- Supportedcites [8] Fleischhacker WW Hobart M Ouyang J Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study Int J Neuropsychopharmacol 2017 20 1 11 21 27566723 PMC5412583 source
The Results > Safety passage reports potentially clinically relevant weight gain (≥7%) in 11.3% of patients during brexpiprazole stabilization and 5.2% of the brexpiprazole group during maintenance. These are the rates and phases stated in the claim; no page number is provided in our copy. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the majority of patients who did not complete the trial were discontinued by the sponsor following early termination of the study after the first interim analysis (87 of 202 patients in the maintenance phase).”
§ Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy > Methods > Relapse-prevention trial
What the sources say
- Partly supportedcites [8] Fleischhacker WW Hobart M Ouyang J Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study Int J Neuropsychopharmacol 2017 20 1 11 21 27566723 PMC5412583 sourceExperimental — accuracy not yet measured
The Discussion (page not provided) says early termination after the interim analysis was the main reason for discontinuation across all three treatment phases (n=192). The Results say the trial ended after the first interim analysis, and the Abstract reports 202 patients randomized into maintenance. Our copy does not substantiate the specific figure of 87 maintenance-phase patients or say that the sponsor discontinued them. (LLM, conf=0.84)
plainstates a causen = 202- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“greater least-squares mean increase in PANSS score for the placebo group (increase of 11.20 points in the placebo group vs 3.25 points in the brexpiprazole group, last observation carried forward [LOCF]; ANCOVA P=0.0007)”
§ Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy > Methods > Relapse-prevention trial
What the sources say
- Supportedcites [8] Fleischhacker WW Hobart M Ouyang J Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study Int J Neuropsychopharmacol 2017 20 1 11 21 27566723 PMC5412583 source
The Results > Efficacy passage reports least-squares mean PANSS total-score increases of 11.20 points with placebo and 3.25 points with brexpiprazole across the maintenance phase, using LOCF and ANCOVA (P=.0007). (LLM, conf=0.95)
plainn = 200 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“better scores for those on brexpiprazole vs placebo on the PSP and Global Assessment of Functioning scales (LOCF P<0.01).”
§ Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy > Methods > Relapse-prevention trial
What the sources say
- Supportedcites [8] Fleischhacker WW Hobart M Ouyang J Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study Int J Neuropsychopharmacol 2017 20 1 11 21 27566723 PMC5412583 source
The Results > Efficacy passage reports that, in the maintenance phase, brexpiprazole was favored over placebo at week 52 on both PSP and GAF scores using LOCF analysis (P<.01). The paper identifies GAF as the Global Assessment of Functioning scale. (LLM, conf=0.95)
plainstates a causen = 200 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the only other significant differences between the placebo and treatment groups in the maintenance phase were increases in fasting triglycerides ≥50 mg/dL in 16.3% of the brexpiprazole group vs 7.4% of the placebo group.”
§ Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy > Methods > Relapse-prevention trial
What the sources say
- Partly supportedcites [8] Fleischhacker WW Hobart M Ouyang J Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study Int J Neuropsychopharmacol 2017 20 1 11 21 27566723 PMC5412583 sourceExperimental — accuracy not yet measured
The Results > Safety passage reports that a ≥50 mg/dL increase in fasting triglycerides occurred in 16.3% of the brexpiprazole group versus 7.4% of the placebo group during maintenance. It describes the incidence as higher, but does not establish that this difference was statistically significant or that it was the only other significant difference. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
43 more claims · 7 with their cited sources checked
Create a free account to see all 97 claims and to verify the 12 references still open.
- It may state two separate claims as one. 40
- Probably not a substantial claim. 19
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy > Methods > Relapse-prevention trial
“The conversion phase was completed over 1–4 weeks at the investigators’ discretion”
§ Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy > Discussion > Titration considerations
“more gradual cross-titration (over 22–33 days) may improve tolerability”
Citations
Cites
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
Maeda, K., Sugino, H., Akazawa, H., Amada, N., Shimada, J., Futamura, T., Yamashita, H., Ito, N., McQuade, R. D., Mørk, A., et al. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213793 · Cited by 372 · cited 3×
“Ideally, the high affinity for the 5HT 1A and 5HT 2A receptors, paired with lower intrinsic activity at D 2 , would translate to clinically favorable antipsychotic efficacy, while avoiding adverse events (AEs) associated with potent agonism or antagonism of the D 2 receptor.(11) Similarly, moderate to low affinity for…”
InfluentialKane, J. M., Skuban, A., Ouyang, J., Hobart, M., Pfister, S., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.038 · Cited by 325 · cited 1×
“…on previous research efforts by enrolling patients from up to three prior phase III studies, including the aforementioned investigation by Fleischhacker et al 8 and two 6-week acute efficacy trials, 4,5 in addition to patients who had never previously participated in a brexpiprazole study.”
Correll, C. U., Skuban, A., Ouyang, J., Hobart, M., Pfister, S., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14101275 · Cited by 183
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., McQuade, R. D., Carson, W. H., Nyilas, M., Sanchez, R., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09688 · Cited by 182
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Zhang, P., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09689 · Cited by 165
Frankel, J. S., & Schwartz, T. L. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316672136 · Cited by 145 · cited 1×
“Similarly, moderate to low affinity for the H 1 and M 1 receptors is expected to correlate with low propensity for sedation, weight gain, and anticholinergic side effects like xerostomia and constipation.(12)”
Citrome, L. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12752 · Cited by 107 · cited 1×
“Introduction Brexpiprazole is among the newest dopamine D 2 partial agonist antipsychotics in a class that includes aripiprazole and cariprazine, and has a unique receptor-binding profile.(1,2) The US Food and Drug Administration (FDA) approved brexpiprazole in 2015 for the treatment of schizophrenia and as an adjunct…”
Self-citationDurgam, S., Earley, W. R., Li, R., Li, D., Lu, K., Laszlovszky, I., Fleischhacker, W. W., & Nasrallah, H. A. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.06.030 · Cited by 107
Citrome, L. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000665 · Cited by 92 · cited 1×
“Ultimately, brexpiprazole and paliperidone were the only two agents that were neither activating nor sedating in patients being treated for acute schizophrenia.(19) Although these effects were examined in acutely ill persons with schizophrenia, the potential for persistence of these effects is a consideration when con…”
Self-citation
Cited by
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia
Keks, N. A., Hope, J., Schwartz, D., McLennan, H., Copolov, D., & Meadows, G. N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00718-4 · Cited by 77
“A recent review of brexpiprazole concluded that in this open-label comparison of brexpiprazole and aripiprazole, there were similar rates of weight gain with the two drugs [107].”
BackgroundPrescriber's Guide: Stahl's Essential Psychopharmacology
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275 · Cited by 87
Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia
Madireddy, S., & Madireddy, S. (2020) · Brain Sciences · doi:10.3390/brainsci10100742 · Cited by 61
New Antipsychotic Medications in the Last Decade
Pahwa, M., Sleem, A., Elsayed, O. H., Good, M. E., & El‐Mallakh, R. S. (2021) · Current Psychiatry Reports · doi:10.1007/s11920-021-01298-w · Cited by 58
Caraci, F., Santagati, M., Caruso, G., Cannavò, D., Leggio, G. M., Salomone, S., & Drago, F. (2020) · F1000Research · doi:10.12688/f1000research.22662.1 · Cited by 50
Metadata
- Authors
- Ward, K., & Citrome, L.
- Affiliations
- University of Michigan (US)
- New York Medical College (US)
- Corresponding author
- Citrome, Leslie
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2019-01
- Volume
- Volume 15
- Pages
- 247-257
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC6339638
- OpenAlex
- W2910694408
- Semantic Scholar
- 1c0cc99088b5fdf9ac621734808cf04cca677b94
- Cited by
- 181
- References
- 27
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 5 · 2023: 2 · 2022: 1 · 2021: 6 · 2020: 163 · 2019: 1
- FWCI
- 34.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Touro Scholar (Touro College) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- University of Michigan
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- brexpiprazole, schizophrenia, maintenance therapy, relapse prevention, dopamine D2 receptor, atypical antipsychotics, akathisia, weight gain, treatment-emergent adverse events, antipsychotic efficacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. https://app.cochat.ai/papers/10.2147/ndt.s169369
- The paper
- Ward, K., & Citrome, L. (2019). Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s169369
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.